PEG-MGF (pegylated mechano growth factor)
PEG-MGF, pegylated MGF, PEGylated IGF-1Ec E-peptide, PEG mechano growth factor
PEG-MGF is the mechano growth factor E-peptide with a polyethylene glycol chain attached, sold on the premise that pegylation makes it last longer in the body. Pegylation is a legitimate and well-understood pharmaceutical technique. Its application to this particular peptide has never been described in a peer-reviewed publication, characterised analytically, or tested in any organism. This is among the thinnest evidence bases of any compound sold as a research peptide.
Mechanism
The intended pharmacology is that of the MGF E-peptide, discussed in that record: a 24-residue C-terminal fragment of the IGF-1Ec splice variant, whose activity, on the best current evidence, depends on the IGF-1 receptor rather than on a dedicated MGF receptor, and whose physiological role appears to lie in modulating IGF-1 processing and local retention rather than in independent ligand action.
Pegylation adds a second, purely pharmacokinetic layer. Covalently attaching polyethylene glycol increases hydrodynamic radius, which slows renal filtration; it sterically shields the peptide backbone from proteases; and it can reduce immunogenicity by masking epitopes. These effects are well documented across licensed pegylated biologics. Crucially, they are also strongly dependent on specifics: which residue the polymer is attached to, whether the attachment is site-specific or heterogeneous, and how large and how branched the polymer is. Attaching PEG at or near a receptor-binding surface can abolish activity outright, and for a 24-residue peptide with no defined tertiary structure, a 5 kDa polymer is roughly twice the mass of the peptide itself and will dominate its behaviour.
For PEG-MGF, none of this is specified. No published work states the conjugation chemistry, the attachment residue, the polymer mass, the degree of substitution, or whether the resulting conjugate retains any measurable biological activity. Every claim about how PEG-MGF behaves is a general statement about pegylation being applied, untested, to an uncharacterised conjugate of a peptide whose own mechanism is unsettled.
What the research shows
A search for 'PEG-MGF' or for pegylated mechano growth factor returns essentially nothing on the conjugate. There is no synthesis and characterisation paper, no in vitro potency comparison against unmodified MGF, no animal pharmacokinetic study, no toxicology package and no clinical trial. ClinicalTrials.gov has no record of it. This is not a case of thin or conflicting evidence; it is an absence of evidence.
What can be said is inherited from the parent peptide and is set out in the MGF record: the IGF-1Ec splice variant is genuinely induced in mechanically loaded muscle, the isolated synthetic E-peptide has effects in cell culture and rodents at concentrations well above physiological, its central marketing claim of IGF-1R-independent signalling has been directly contradicted, and no MGF-specific receptor has ever been found. Pegylating a molecule does not improve the evidence for what that molecule does.
The most informative recent literature is not about efficacy at all. A 2026 review in Frontiers in Endocrinology surveyed the gap between the clinical evidence base for peptides that modulate the growth hormone and IGF-1 axis and the scale of unsupervised self-administration of those same compounds. PEG-MGF sits squarely in that gap: a product whose entire proposition, improved duration of action, is a manufacturing claim that no one has verified, applied to a biological claim that has not been substantiated.
Evidence assessment
Preclinical only
Assigned the lowest available tier, and even that overstates the position: there is no published study of the pegylated conjugate itself in any species or system, so the tier reflects the underlying MGF peptide literature rather than PEG-MGF.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration Preclinical only
Found the case for MGF as an independent growth factor weak, with no identified receptor and a literature dominated by supraphysiological synthetic peptide concentrations.
Insulin-like growth factor-I E-peptide activity is dependent on the IGF-I receptor Preclinical only
E-peptide effects required a functional IGF-1 receptor, undercutting the claim of a distinct MGF signalling pathway.
Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls Limited evidence
Established the analytical signature of biotechnologically produced MGF for anti-doping detection.
Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H Limited evidence
Confiscated material contained a sequence-modified MGF analogue (R23H) engineered for proteolytic resistance, illustrating how far marketed products diverge from characterised compounds.
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Limited evidence
Documents a substantial and widening gap between the clinical evidence base for these peptides and the scale of unsupervised self-administration.
Safety
No safety data exist. No toxicology study, no human exposure record, no adverse-event surveillance.
The risks specific to pegylation deserve mention because they are real and frequently overlooked. Anti-PEG antibodies are common in the general population as a consequence of PEG exposure in cosmetics, foods and medicines, and pre-existing or treatment-induced anti-PEG antibodies can cause accelerated blood clearance of pegylated products and, in some cases, hypersensitivity and infusion-type reactions. Repeated administration of an unlicensed pegylated peptide carries that risk without any of the monitoring that accompanies a licensed pegylated medicine. Separately, PEG accumulation in tissue is a recognised concern for pegylated therapeutics given chronically, and has been the subject of regulatory attention for licensed products where cumulative exposure is high.
The compounding problem is manufacturing. Site-specific pegylation is technically demanding. Heterogeneous conjugation produces a mixture of positional isomers with differing activity, and unreacted PEG reagent, free peptide and multiply-pegylated species are all plausible contaminants. There is no published independent analysis of any commercial PEG-MGF product, so the actual composition of what is sold under this name is unknown. Combined with the absence of any biological data on the conjugate, the honest summary is that a purchaser of PEG-MGF cannot say what molecule they have, what it does, or how long it persists.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation and no clinical trial authorisation. Supplying it for human use breaches the Human Medicines Regulations 2012. Not controlled under the Misuse of Drugs Act 1971. |
| United States | Not approved by FDA, never studied under an investigational new drug application, and not a dietary supplement. Marketing it for human use makes it an unapproved new drug and misbranded under the Federal Food, Drug, and Cosmetic Act. It exists solely within the online research-chemical market under a 'for research use only' label. Not DEA-scheduled. |
| WADA (sport) | Prohibited at all times. The WADA Prohibited List, section S2.3, names 'Mechano Growth Factors (MGFs)', and the list applies to substances with similar chemical structure or similar biological effect; a pegylated MGF conjugate is covered on both grounds. Class S2 substances are non-Specified Substances. |
Questions
Nobody has measured it. Pegylation does reliably extend circulating half-life for well-characterised biologics, and that is the rationale offered for the product. But no pharmacokinetic study of PEG-MGF has been published in any species, and no vendor discloses the polymer size or attachment site, both of which determine the magnitude of any extension. Specific half-life figures quoted commercially are not traceable to any primary data.
There is no comparison to draw on. No study has compared pegylated and unmodified MGF for potency, duration or anything else. It is worth noting that pegylation can reduce or abolish activity if the polymer is attached near a binding surface, and for a 24-residue peptide a typical PEG chain is heavier than the peptide itself. Without characterisation data, 'better' is not a claim that can be evaluated.
Yes. Anti-PEG antibodies are widespread in the general population from everyday PEG exposure, and they can cause accelerated clearance of pegylated products and hypersensitivity reactions. Licensed pegylated medicines are monitored for this. An unlicensed pegylated peptide of unknown conjugation chemistry carries the same immunological risk with none of the monitoring, and there is no published analysis of what commercial PEG-MGF products actually contain.
No. There is no clinical trial, no published human administration study, and no toxicology package. Searches of PubMed and ClinicalTrials.gov return nothing on the conjugate. This is not a compound with weak evidence; it is a compound with no evidence.